BioNTech COO entity sells 50,000 shares

BioNTech SE Chief Operating Officer Sierk Poetting reported an indirect open-market sale of 50,000 Ordinary Shares.

Rhea-AI Filing Summary

BioNTech SE Chief Operating Officer Sierk Poetting reported an indirect open-market sale of 50,000 Ordinary Shares. The shares were sold at an average price of $110.5592 per share and are held through Tofino GmbH, a company of which Poetting is the sole shareholder.

After this transaction, indirect holdings reported for Poetting through Tofino GmbH total 399,387 Ordinary Shares. This filing reflects a net sale, with no option exercises or derivative transactions disclosed in this report.

Insights

Equity compensation and insider-trading analyst

COO’s entity sells 50,000 BioNTech shares, retaining a large remaining stake.

The filing shows Tofino GmbH, wholly owned by BioNTech’s COO Sierk Poetting, executed an open-market sale of 50,000 Ordinary Shares at $110.5592 per share. This is a straightforward sale, with no associated option exercises or tax-withholding events.

Post-transaction, 399,387 Ordinary Shares remain indirectly held through Tofino GmbH, indicating the COO still has substantial exposure. With only one net-sell transaction and no broader pattern in this excerpt, the event appears as a notable but singular liquidity move rather than a structural change.

Insider Trade Summary 10b5-1

Net Seller: 50,000 shares

Net Sell 1 txn

Insider Poetting Sierk

Role Chief Operating Officer

Sold 50,000 shs ($5.53M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	50,000	$110.5592	$5.53M

Holdings After Transaction: Ordinary Shares — 399,387 shares (Indirect, See Footnote)

Footnotes (1)

1. F1. The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH.

Key Figures

Shares sold: 50,000 shares Average sale price: $110.5592 per share Shares held after sale: 399,387 shares +1 more

4 metrics

Shares sold 50,000 shares Open-market sale of Ordinary Shares

Average sale price $110.5592 per share Price for 50,000 Ordinary Shares sold

Shares held after sale 399,387 shares Indirect holdings via Tofino GmbH following transaction

Net shares sold 50,000 shares Net-sell direction in transaction summary

Key Terms

open-market sale, indirect ownership, beneficially own

3 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

""direct_or_indirect": "I","nature_of_ownership": "See Footnote""

beneficially own financial

"may be deemed to beneficially own the ordinary shares held"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioNTech (BNTX) report for COO Sierk Poetting?

BioNTech reported that an entity associated with COO Sierk Poetting sold 50,000 Ordinary Shares in an open-market transaction. The shares were held indirectly through Tofino GmbH, which is wholly owned by Poetting and may make him a beneficial owner of those shares.

At what price were the BioNTech (BNTX) shares sold in this Form 4 filing?

The 50,000 BioNTech Ordinary Shares were sold at an average price of about $110.5592 per share. This reflects the weighted-average sale price for the reported open-market transaction on the disclosed date in the Form 4 filing.

How many BioNTech (BNTX) shares does COO Sierk Poetting hold after the sale?

After the reported sale, Sierk Poetting is shown as indirectly holding 399,387 Ordinary Shares of BioNTech. These shares are held through Tofino GmbH, where Poetting is the sole shareholder and may be deemed to beneficially own the entity’s holdings.

Is the BioNTech (BNTX) COO’s sale a direct or indirect shareholding change?

The sale involves indirect ownership. The Form 4 notes the shares are held by Tofino GmbH, not by Sierk Poetting personally. He is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by that entity.

Does this BioNTech (BNTX) Form 4 include any option exercises or derivatives?

No, this Form 4 only reports a sale of Ordinary Shares and shows no derivative transactions. The derivative summary is empty, indicating there were no option exercises, conversions, or other derivative-related events disclosed in this particular insider transaction report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poetting Sierk

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/22/2026		S		50,000	D	$110.5592	399,387	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH.

Remarks:

	/s/ Humza Bokhari, Attorney-in-Fact	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)